In fairness, the quarterly did mention DEP Gemcitabine as (still) at the pre-clinical stage. I wonder if they are trying to find someone else to pay for the trial? Regardless of how long it takes.
Business development activities for DEP® cabazitaxel, DEP® irinotecan, and DEP® docetaxel are ongoing. Other internal preclinical DEP® programs including DEP® radiotheranostics, DEP® ADCs, and DEP® gemcitabine continue to progress, with ongoing commercial discussions in parallel.
In fairness, the quarterly did mention DEP Gemcitabine as...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
